During the past several years, new developments in endovascular intervention have led to a paradigm shift in the treatment of cerebrovascular disease, resulting in a significant increase in the employment of endovascular therapies.. As a result, the neurovascular market has been growing rapidly, and is estimated to continue growing from approximately $1.3 billion in 2014 to $1.7 billion in 2017.
Stroke is the fourth most common cause of death in industrialized nations and the single most common cause of permanent disability. Each year, approximately 800,000 Americans experience a new or recurrent stroke. Approximately 25% those experiencing an initial stroke die within one year, 30%-50% of stroke survivors never regain functional independence, and 15%-30% are permanently disabled. Thus, stroke represents a massive financial and personal burden, with direct and indirect annual costs in the U.S. estimated to total over $73 billion (2010).